Bromocriptine_Mesylate: profile and news

Mylan Reports Fiscal 2005 Earnings Per Diluted Share of $0.74 ... May 12, 2005
In fiscal 2006 to date, the Company has received final ANDA approval for bromocriptine mesylate capsules and anagrelide hydrochloride capsules and tentative ... - Yahoo News

Other information

Indication
For treatment of idiopathic or postencephalitic Parkinson's disease, dysfunctions associated with hyperprolactinemia and in the treatment of acromegaly

Pharmacology
Bromocriptine is an ergoline derivitave dopamine agonist that is used in the treatment of amenorrhea, female infertility, abnormal discharge of breast milk, hypogonadism, Parkinson's disease, and acromegaly. Bromocriptine produces its therapeutic effect in the treatment of Parkinson's disease, a clinical condition characterized by a progressive deficiency in dopamine synthesis in the substantia nigra, by directly stimulating the dopamine receptors in the corpus striatum.

Mechanism Of Action
Bromocriptine acts by directly stimulating the dopamine receptors in the corpus striatum.

Drug Category
Antiparkinson Agents; Antidyskinetics; Unclassified Therapeutic Agents (92:00.00); ATC:G02CB01; ATC:N04BC01

Brand Names/Synonyms
Alti-Bromocriptine; Apo-Bromocriptine; Bromergocryptine; Bromocriptin; Bromocriptina [Inn-Spanish]; Bromocriptine; Bromocriptine Mesylate; Bromocriptine Methanesulfonate; Bromocriptine [Usan:Ban:Inn]; Bromocriptinum [Inn-Latin]; Bromocryptine; Bromocryptine Mesylate; Bromoergocriptine; Bromoergocryptine; CB 154; CB-154; CCRIS 3244; Parlodel; Parlodel Snaptabs

Dosage Forms
CAPSULE

Absorption
Not Available

Interactions
Interactions for Bromocriptine:

The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate. Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents. Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide. Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.

Chemical IUPAC Name
Not Available

Chemical Formula
C32H40BrN5O5

Half Life
4-15 hours

Drug Type
Approved Drug

# Accession No
APRD00622

CAS Registry Number
25614-03-3